August 5, 2020 Microscopy PR/Corporate

【Delayed】Consolidated Financial Statements for the First Quarter Ended June 30, 2020 FY2021 (April 1, 2020 – June 30, 2020)

Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relstions Japanese... Read more

August 5, 2020 Uncategorized

【Delayed】Announcement on revision of financial forecast

Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relstions Japanese... Read more

June 8, 2020 PAI Top-10

Takara Bio Group’s Formulation of Long-Term Management Plan FY2026 and Medium-Term Management Plan FY2023

This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more

May 14, 2020 PR/Corporate

Summary of Financial Results 2020

Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relstions Japanese... Read more

May 13, 2020 Bio/Pharma/CRO M&A, Partnerships

【Delayed】Takara Bio has entered into a license agreement relating to C-REV with Tasly Biopharmaceuticals, China

Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relstions Japanese... Read more

February 13, 2020 Atomic Spectroscopy Microscopy PR/Corporate

Consolidated Financial Statements for the Third Quarter Ended December 31, 2019 FY2020 (April 1, 2019 – March 31, 2020)[UNAUDITED]

About Us Message from the president Corporate Data and Subsidiaries Corporate Executives Directions to Takara Bio Quality Assurance Policy Consolidated Subsidiaries Business Outline Bioindustry Gene Therapy News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline... Read more

January 21, 2020 Clinical Research/Diagn.

Takara Bio Launches a New Facility for the Research and Manufacturing of Regenerative Medicine Products

2020/01/21 Kusatsu/Shiga Japan – January 21, 2020 – Takara Bio Inc. (Takara Bio), announced completion of a new facility, the Center for Gene and Cell Processing II (new facility) for the research and manufacturing of regenerative medicine products in Kusatsu, Shiga and operation start since January 2020.   Takara Bio constructed a Center for Gene... Read more

December 23, 2019 Uncategorized

Takara Bio Report2019

About Us Message from the president Corporate Data and Subsidiaries Corporate Executives Directions to Takara Bio Quality Assurance Policy Consolidated Subsidiaries Business Outline Bioindustry Gene Therapy News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline... Read more

May 7, 2019 Bio/Pharma/CRO Licensing, IP, and Legal

A wholly-owned subsidiary, Takara Biotechnology (Dalian) Co., Ltd. Acquires ISO:13485 certification

2019/05/07 Kusatsu/Shiga, Japan – April 24, 2019 –  Takara Bio Inc. (Takara Bio) announced that Takara Biotechnology (Dalian) Co., Ltd. (Dalian city, China, hereafter “Takara Biotechnology (Dalian)”), a wholly-owned subsidiary of Takara Bio has acquired ISO 13485:2016 certification, an international standard for quality management system of medical devices and diagnostic pharmaceuticals.   Takara Biotechnology (Dalian) is a... Read more